Literature DB >> 19835720

Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain.

Lorenzo Arribas-Mir1, Dolores Rueda-Lozano, María Agrela-Cardona, Tania Cedeño-Benavides, Carmen Olvera-Porcel, Aurora Bueno-Cavanillas.   

Abstract

BACKGROUND: User profile, continuation rate, reasons for discontinuation, problems during insertion and removal, and effectiveness of an etonogestrel subdermal contraceptive implant (ESCI) were assessed. STUDY
DESIGN: A follow-up of 372 women 3 years after insertion of an ESCI performed by family physicians in Granada, Spain, by means of consultations, examination of medical records and telephone interviews.
RESULTS: Data were available for 356 (95.7%) women. The average age was 27.2 years, and 159 (42.7%) were nulliparous. Continuation rates were 91.0% at 1 year, 74.7% at 2 years and 65.1% at 2 years and 9 months. The main reasons for discontinuation were excessive bleeding (44, 12.4%), wish to become pregnant (44, 12.4%) and side effects not related to menstruation (21, 5.9%). However, 141 (39.6%) received a second implant when the first one expired. No pregnancy occurred in 893.4 women-years.
CONCLUSIONS: Family physicians can achieve excellent results with the ESCI. It should be included in the range of contraceptives offered by primary care physicians.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835720     DOI: 10.1016/j.contraception.2009.04.003

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

1.  Continuation of reversible contraception in teenagers and young women.

Authors:  Jessica R Rosenstock; Jeffrey F Peipert; Tessa Madden; Qiuhong Zhao; Gina M Secura
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

Review 2.  Contraceptive failure in the United States.

Authors:  James Trussell
Journal:  Contraception       Date:  2011-03-12       Impact factor: 3.375

3.  Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period.

Authors:  Candan İltemir Duvan; Elif Gözdemir; Ikbal Kaygusuz; Zeynep Kamalak; Nilgün Öztürk Turhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-09-01

Review 4.  There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes.

Authors:  Chelsea B Polis; Rubina Hussain; Amanda Berry
Journal:  Reprod Health       Date:  2018-06-26       Impact factor: 3.223

5.  [Use of contraception with only progestogens in primary care: Study GESTAGAP].

Authors:  Raquel Rodríguez-Rodríguez; Elena Polentinos-Castro; Amaya Azcoaga-Lorenzo; Cristina González-Fernández
Journal:  Aten Primaria       Date:  2018-08-13       Impact factor: 1.137

6.  A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.

Authors:  Kusum V Moray; Himanshu Chaurasia; Oshima Sachin; Beena Joshi
Journal:  Reprod Health       Date:  2021-01-06       Impact factor: 3.223

7. 

Authors:  Alberto López García-Franco; José Antonio Baeyens Fernández; Emilia Bailón Muñoz; M José Iglesias Piñeiro; Isabel Del Cura González; Amparo Ortega Del Moral; Jacinta Landa Goñi; Pablo Alonso Coello; Lorenzo Arribas Mir
Journal:  Aten Primaria       Date:  2018-05       Impact factor: 1.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.